The Influenza B/Yamagata lineage appears to become extinct: implications for quadrivalent influenza vaccines?
Chair

Nationality: Dutch
Position: Founding Director of the Center of Infection Medicine and Zoonosis Research and Guest-Professor at the University of Veterinary Medicine Hannover
Research fields: Virus infections of humans and animals
Professor Osterhaus is the Founding Director of the Center of Infection Medicine and Zoonosis Research at the University of Veterinary Medicine Hannover, Germany, and cofounder/CSO of Viroclinics-DDL BV (currently part of CERBA) and ViroNative BV (both spin-outs of Erasmus MC) and CR2O. He was head of the Department of Viroscience at Erasmus MC Rotterdam until 2014.
He has a long track record as a researcher and project leader of numerous major scientific projects. At Erasmus MC, he has run a diagnostic virology lab with more than 40 staff and a research virology lab with over 150 personnel. His research programme follows an integrated “viroscience” concept, bringing together world-leading scientists in molecular virology, immunology, epidemiology, pathogenesis, and intervention studies for human and animal virus infections.
Among his major accomplishments are the discovery of more than 80 viruses of humans and animals (e.g. human metapneumovirus, coronaviruses, influenza viruses), elucidation of the pathogenesis of major human and animal virus infections, and development of novel intervention strategies. This has enabled health authorities like the WHO to effectively combat disease outbreaks like SARS and avian influenza. The established spin-outs are among his other societally relevant successes, allowing effective testing and refining of diagnostic tools and other intervention strategies.
Professor Osterhaus has acted as mentor for more than 85 PhD students and holds several key patents. He is the author of more than 1360 scientific papers in peer-reviewed journals, together cited > 90,000 times with an H index > 145. He holds several senior editorships and has received numerous prestigious awards. He is a member of the Dutch and German National Academies of Sciences, member of the Belgium Academia of Medicine, and Commander of the Order of the Dutch Lion.
- Intervention Strategies: hMPV - the (not so) new kid on the block
- Flu vaccines - advancements, challenges, and global impact
- Which viruses could cause the next pandemic?
- Which viruses could cause the next pandemic?
- Will there be a new pandemic? When will it be and are we better prepared for it this time around?
- Is COVID-19 worse than influenza?
- Scientific highlights of the 9th ESWI Influenza Conference
- ESWI Summit 2024: Rapporteur from the RSVVW’ 2024 meeting in Mumbai
- Webinar: Immunisation & Treatment
- ESWI Respiratory Virus Summit 2024
- The Ninth ESWI Influenza Conference: Highlights
- The Influenza B/Yamagata lineage appears to become extinct: implications for quadrivalent influenza vaccines?
- RSV looking towards the future
- ESWI pandemic preparedness summit: where science and policy meet
- Respiratory Virus Summit 2023
- Celebrating ESWI 30 years!
- “Flu, COVID and RSV: How to vaccinate?” symposium at Options XI
- ESWI Summit 2022 – Stakeholder Debate
- ESWI Summit 2022 - Conclusions
- World Influenza Conference
- ESWI Summit 2022: Pandemic Preparedness, Where Science and Policy Meet
- Pandemic Preparedness Planning in Peacetime
- World Vaccine Congress Europe 2022
- Flu and COVID-19 booster Vaccinations: where do we go?
- RSV Disease in a COVID-19 era
- COVID-19 Treatment and Medication
- Childhood Influenza Vaccination and treatment in a COVID-19 era
- Vaccination in a COVID-19 era
- Should we introduce national live vaccination programmes for children?
- Influenza in persons living with diabetes: Pathogenesis and prevention
Session information
- Ben Cowling, University of Hong Kong, Hong Kong S.A.R.
- Wenqing Zhang, World Health Organization, Switzerland